News
Preliminary results from a landmark clinical trial suggest that CRISPR-Cas9 gene editing can be deployed directly into the body to treat disease.
The study is the…
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical…
Join moderators Professor Per Westermark and Professor Julian Gillmore for a three-hour seminar that will provide an overview of current methods used to diagnose…
This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.
Together with the ISA Board…
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced that the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi…
Outside of specialized centers, access to the appropriate typing and studies for risk stratification as well as novel therapeutic options is still suboptimal.…
AL Amyloidosis and Agent Orange
Veterans who develop AL amyloidosis and were exposed to Agent Orange or other herbicides during military service do not have to…
The results of the phase 1 study open-label trial showed the therapy was safe, raising the possibility of a more effective and more appealing treatment for the…
Webinar AL Amyloidosis
On October 26, 2021 the first ever World Amyloidosis Day will be organized by Amyloidosis Alliance and patient organisations from 18…
This year's event is dedicated to the passionate and growing community of amyloid patients, care providers, researchers and clinicians both locally and around the…